FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W91433150> ?p ?o ?g. }

• W91433150 abstract "Abstract Poor prognosis DLBCL, including intermediate and high risk disease according to IPI accounts for approximately 20% of new cases of DLBCL. The addition of rituximab to conventional chemotherapy (CHOP) has improved the outcomes in this subset, with a 2-year overall survival (OS) of about 50%. However, 40-50% of these patients still have either primary refractory disease or relapse after an initial response. Rituximab-EPOCH (R-EPOCH), an infusional regimen has a dynamic dose adjustment strategy based on the hematopoietic nadir in previous cycle to achieve an optimal drug concentration. Phase II studies with R-EPOCH in untreated DLBCL with intermediate and high risk IPI have reported improved outcomes, with an estimated 2-year OS of 75% which appears superior to that of R-CHOP. Hence we analysed the outcomes of patients with de-novo, poor prognosis (intermediate and high risk IPI) DLBCL who received R-EPOCH and compared it to the historical cohort of patients who were treated with R CHOP at our centre. Methods Treatment-naïve patients of DLBCL with intermediate or high risk IPI, registered at our centre between November 2011 to June 2013, who received R-EPOCH regimen, were included for the analysis. Case records were reviewed for – demography, histology, stage, bulk of disease, extranodal sites, performance status, IPI, LDH, albumin, details of chemotherapy, grade ¾ toxicities (CTCAE version 4) and need for hospitalization. Responses were evaluated at mid and end of chemotherapy. Overall and progression free survival were calculated. Similar analysis was done for poor prognosis DLBCL patients treated with R-CHOP between Jan 2007 to December 2010. Results Baseline characteristics and treatment outcomes of 32 patients (males-24, females-8) treated with R-EPOCH were compared to 42 patients (males-28, females-14) who received R- CHOP. Median age in R- EPOCH group was 47 years (range-20-75 years) versus 55 years (23-72 years )in R- CHOP. Performance status≥ 2 was seen in 47% in R- EPOCH as compared to 28% in R-CHOP group. Significant proportion of patients in R-EPOCH had bulky disease(81% versus 16%) and stage III/IV disease (90% versus 81%) as compared to R-CHOP. Patients with IPI of two represented 8(25%), IPI of three, 11(34%), and IPI of four and five, 10(32%) on R- EPOCH compared to 21(50%), 19(45%) and 2(5%) on R-CHOP, respectively. Serum albumin<3.5 gm/dL was seen in 10(32%) on R-EPOCH and 14(33%) on R-CHOP. LDH was elevated in all but two patients on R-EPOCH compared to 37(88%) patients on R-CHOP. Complete response was seen in 60%, and disease progression in 18% patients on R-EPOCH, compared to 59%, and 20% on R-CHOP respectively. There were 5 deaths on R-EPOCH, 3 due to toxicity and 2 due to disease progression, and in comparison there were 4 deaths on R-CHOP, all of them due to disease progression. With a median follow up of 6 months, the estimated OS at 1 year is 74% and progression free survival (PFS) is 62% for patients on R- EPOCH. For patients on R- CHOP, with a median follow up of 31 months, 1 year OS is 68% and PFS is 64%. Conclusion Our retrospective analysis indicates that treatment with R-EPOCH regimen resulted in similar results as with R-CHOP regimen. However patients treated with R-EPOCH had more adverse features in terms of disease bulk, poor performance status and high IPI score. A prospective randomized comparison is warranted between these two regimens. Disclosures: No relevant conflicts of interest to declare." @default.
• W91433150 created "2016-06-24" @default.
• W91433150 creator A5017405089 @default.
• W91433150 creator A5028533298 @default.
• W91433150 creator A5029787002 @default.
• W91433150 creator A5032568030 @default.
• W91433150 creator A5042200616 @default.
• W91433150 creator A5044401924 @default.
• W91433150 creator A5058364259 @default.
• W91433150 creator A5066582496 @default.
• W91433150 creator A5066889618 @default.
• W91433150 creator A5069322918 @default.
• W91433150 creator A5087669794 @default.
• W91433150 date "2013-11-15" @default.
• W91433150 modified "2023-09-29" @default.
• W91433150 title "Comparison Of Treatment Outcomes with EPOCH-Rituximab Versus CHOP-Rituximab in Patients with De-novo Intermediate and High Risk International Prognostic Index(IPI)Diffuse Large B Cell Lymphoma(DLBCL): A Single Center Retrospective Analysis" @default.
• W91433150 doi "https://doi.org/10.1182/blood.v122.21.5115.5115" @default.
• W91433150 hasPublicationYear "2013" @default.
• W91433150 type Work @default.
• W91433150 sameAs 91433150 @default.
• W91433150 citedByCount "1" @default.
• W91433150 countsByYear W914331502016 @default.
• W91433150 crossrefType "journal-article" @default.
• W91433150 hasAuthorship W91433150A5017405089 @default.
• W91433150 hasAuthorship W91433150A5028533298 @default.
• W91433150 hasAuthorship W91433150A5029787002 @default.
• W91433150 hasAuthorship W91433150A5032568030 @default.
• W91433150 hasAuthorship W91433150A5042200616 @default.
• W91433150 hasAuthorship W91433150A5044401924 @default.
• W91433150 hasAuthorship W91433150A5058364259 @default.
• W91433150 hasAuthorship W91433150A5066582496 @default.
• W91433150 hasAuthorship W91433150A5066889618 @default.
• W91433150 hasAuthorship W91433150A5069322918 @default.
• W91433150 hasAuthorship W91433150A5087669794 @default.
• W91433150 hasConcept C121332964 @default.
• W91433150 hasConcept C126322002 @default.
• W91433150 hasConcept C1276947 @default.
• W91433150 hasConcept C141071460 @default.
• W91433150 hasConcept C143998085 @default.
• W91433150 hasConcept C150846664 @default.
• W91433150 hasConcept C2776694085 @default.
• W91433150 hasConcept C2778336483 @default.
• W91433150 hasConcept C2778476033 @default.
• W91433150 hasConcept C2778559949 @default.
• W91433150 hasConcept C2779338263 @default.
• W91433150 hasConcept C2779709957 @default.
• W91433150 hasConcept C2779725641 @default.
• W91433150 hasConcept C2780317896 @default.
• W91433150 hasConcept C2780653079 @default.
• W91433150 hasConcept C2781413609 @default.
• W91433150 hasConcept C71924100 @default.
• W91433150 hasConceptScore W91433150C121332964 @default.
• W91433150 hasConceptScore W91433150C126322002 @default.
• W91433150 hasConceptScore W91433150C1276947 @default.
• W91433150 hasConceptScore W91433150C141071460 @default.
• W91433150 hasConceptScore W91433150C143998085 @default.
• W91433150 hasConceptScore W91433150C150846664 @default.
• W91433150 hasConceptScore W91433150C2776694085 @default.
• W91433150 hasConceptScore W91433150C2778336483 @default.
• W91433150 hasConceptScore W91433150C2778476033 @default.
• W91433150 hasConceptScore W91433150C2778559949 @default.
• W91433150 hasConceptScore W91433150C2779338263 @default.
• W91433150 hasConceptScore W91433150C2779709957 @default.
• W91433150 hasConceptScore W91433150C2779725641 @default.
• W91433150 hasConceptScore W91433150C2780317896 @default.
• W91433150 hasConceptScore W91433150C2780653079 @default.
• W91433150 hasConceptScore W91433150C2781413609 @default.
• W91433150 hasConceptScore W91433150C71924100 @default.
• W91433150 hasLocation W914331501 @default.
• W91433150 hasOpenAccess W91433150 @default.
• W91433150 hasPrimaryLocation W914331501 @default.
• W91433150 hasRelatedWork W1127693041 @default.
• W91433150 hasRelatedWork W2076770812 @default.
• W91433150 hasRelatedWork W2118061166 @default.
• W91433150 hasRelatedWork W2530156434 @default.
• W91433150 hasRelatedWork W2552475722 @default.
• W91433150 hasRelatedWork W2554523872 @default.
• W91433150 hasRelatedWork W2556509969 @default.
• W91433150 hasRelatedWork W2560837841 @default.
• W91433150 hasRelatedWork W2585399163 @default.
• W91433150 hasRelatedWork W2780959200 @default.
• W91433150 hasRelatedWork W2896058378 @default.
• W91433150 hasRelatedWork W2953511027 @default.
• W91433150 hasRelatedWork W2965765526 @default.
• W91433150 hasRelatedWork W2972334395 @default.
• W91433150 hasRelatedWork W2973007522 @default.
• W91433150 hasRelatedWork W2979574056 @default.
• W91433150 hasRelatedWork W2979906622 @default.
• W91433150 hasRelatedWork W2979942928 @default.
• W91433150 hasRelatedWork W3030296130 @default.
• W91433150 hasRelatedWork W3097763740 @default.
• W91433150 isParatext "false" @default.
• W91433150 isRetracted "false" @default.
• W91433150 magId "91433150" @default.
• W91433150 workType "article" @default.